Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers

View Full Paper

Ask AI

Bookmark

Why the study?

Does CYP2D6 metabolizer status affect the steady-state pharmacokinetics of nebivolol in healthy adults?

Structured PICO

Does CYP2D6 metabolizer status affect the steady-state pharmacokinetics of nebivolol in healthy adults?

Population

22 healthy adult subjects (16 extensive CYP2D6 metabolizers and 6 poor CYP2D6 metabolizers)

Intervention

Nebivolol 10 mg once daily for 14 days

Comparator

Extensive vs Poor CYP2D6 metabolizers

Outcome

Steady-state pharmacokinetics of nebivolol and nebivolol glucuronides (AUC, Cmax, Tmax, t1/2, CI/F) on Day 14surrogate

Despite significant pharmacokinetic differences between extensive and poor CYP2D6 metabolizers, nebivolol is well tolerated in both groups.

Authors

No takes yet. Share an insight, caveat, or question.

Tolerability maintained despite higher exposure in poor metabolizers; extends CYP2D6 PK data but leaves dosing implications open in patients.

SHAW et al. (2005) studied this question.

View Full Paper

Ask AI

Bookmark

Tolerability maintained despite higher exposure in poor metabolizers; extends CYP2D6 PK data but leaves dosing implications open in patients.